New study probes protein levels to predict drug response in head and neck cancer
NCT ID NCT05816785
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 26 times
Summary
This study looks at whether a protein called AXL in head and neck tumors affects how well a combination of two drugs (imatinib and cetuximab) works. About 15 adults with head and neck cancer will receive these drugs in the short window between diagnosis and their standard treatment (surgery or radiation). The main goal is to measure changes in a cell growth marker (Ki67) in tumor samples taken before and after the drug combination. This is an early-phase trial focused on understanding the biology, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.